CClinicalTrials.gg
RecruitingNCT06624969Updated May 5, 2026

Virtual Reality in Reducing Acute Orthopedic Pain

An interventional study of virtual reality in Fractures, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary aim of this research is to show that a virtual reality (VR) service line is feasible and can sustain itself with the ability to take care of patients. Additionally, the investigators aim to learn about the limitations of a service line and provide a pathway for future improvements in building a VR service line that is optimally aligned with the user's needs. Secondary aims are to evaluate the clinical aspects of the patient's outcomes including length of stay, morphine equivalents in pain medicine required during the hospital stay, and user experiences.

02

Conditions studied

  • Fractures

Keywords

  • pain control
  • orthopedic
  • fracture
  • hospital
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Hospitalized with an orthopedic fracture
  2. Able to participate fully in all aspects of the study
  3. Able to understand and sign informed consent
  4. Individuals with unaided vision or those who can correct their vision using contact lenses

Exclusion criteria

Exclusion Criteria:

  1. Non-English speaking
  2. Self-reported history of acute and/or chronic severe motion sickness
  3. The presence of a facial/head deformity that will prohibit the wearing of a VR head mounted display.
  4. Legally blind or deaf
  5. Have had a seizure within the past 1 year
  6. Have current (within the past 30 days) clinically significant acute or chronic progressive or unstable/uncontrolled neurologic disorder
  7. Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Virtual reality

    Intervention with virtual reality

    Other: virtual reality

  • No intervention
    Standard of care

    No virtual reality intervention

Interventions

  • Othervirtual reality

    Virtual reality program to reduce pain in orthopedic fractures

05

What researchers measure

Primary outcomes

  1. opioid use

    Change in opioid equivalents during hospital stay from hospital admission to discharge

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

Secondary outcomes

  1. reduction in anxiolytics

    Change in anxiolytics during the hospital admission from admission to discharge

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

  2. hospital length of stay

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

  3. reduction in sleep aids prescribed

    Change in sleep aids prescribed during the hospital stay from hospital admission to discharge

    Time frame: From date of enrollment which begins at hospital admission until the date of hospital discharge, assessed up to 5 weeks

  4. User experiences

    Subjective user experiences with the virtual reality program obtained at hospital discharge using a questionnaire with Likert scale answers showing higher scores to have better experiences with the intervention

    Time frame: obtained once on the day of hospital discharge, up to 5 weeks from study enrollment

06

Study locations

1 of 1 sites recruiting
  • Mayo Clinic Hospital
    Jacksonville, Florida 32224, United States
    • · Contact · 3142832296
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06624969
Lead sponsor
Mayo Clinic
Responsible party
Scott A. Helgeson (Consultant, Assistant Professor of Medicine, Mayo Clinic) — Principal investigator
First posted
Oct 3, 2024
Start date
Apr 23, 2026
Primary completion
Jan 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 5, 2026

Study contacts

Scott Helgeson, MD
Contact
helgeson.scott@mayo.edu
904-953-2000
Scott Helgeson, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion